DE69900756D1 - Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung - Google Patents

Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung

Info

Publication number
DE69900756D1
DE69900756D1 DE69900756T DE69900756T DE69900756D1 DE 69900756 D1 DE69900756 D1 DE 69900756D1 DE 69900756 T DE69900756 T DE 69900756T DE 69900756 T DE69900756 T DE 69900756T DE 69900756 D1 DE69900756 D1 DE 69900756D1
Authority
DE
Germany
Prior art keywords
production
cytotoxic effect
medicinal products
hmg proteins
hmg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69900756T
Other languages
English (en)
Other versions
DE69900756T2 (de
Inventor
Alberto Bartorelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SICOR Societa Italiana Corticosteroidi SRL
Original Assignee
ISTITUTO DI RECERCHE GIORGIO S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ISTITUTO DI RECERCHE GIORGIO S filed Critical ISTITUTO DI RECERCHE GIORGIO S
Application granted granted Critical
Publication of DE69900756D1 publication Critical patent/DE69900756D1/de
Publication of DE69900756T2 publication Critical patent/DE69900756T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DE69900756T 1998-05-19 1999-05-19 Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung Expired - Fee Related DE69900756T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT98MI001094A IT1299583B1 (it) 1998-05-19 1998-05-19 Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
PCT/EP1999/003431 WO1999059609A2 (en) 1998-05-19 1999-05-19 Use of hmg proteins for the preparation of medicaments having cytotoxic activity

Publications (2)

Publication Number Publication Date
DE69900756D1 true DE69900756D1 (de) 2002-02-28
DE69900756T2 DE69900756T2 (de) 2003-03-13

Family

ID=11380053

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69900756T Expired - Fee Related DE69900756T2 (de) 1998-05-19 1999-05-19 Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung

Country Status (10)

Country Link
EP (1) EP1079849B1 (de)
JP (1) JP2002515445A (de)
AT (1) ATE211391T1 (de)
AU (1) AU4363199A (de)
DE (1) DE69900756T2 (de)
DK (1) DK1079849T3 (de)
ES (1) ES2171086T3 (de)
IT (1) IT1299583B1 (de)
PT (1) PT1079849E (de)
WO (1) WO1999059609A2 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
US20020164644A1 (en) * 2000-04-05 2002-11-07 Ikuro Maruyama Adsorbents for high mobility group proteins and column for purifying body fluid
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
EP1453531B1 (de) * 2001-12-19 2008-05-14 Alcedo Biotech GmbH Verwendung von hmgb-proteinen und dafür codierenden nukleinsäuren
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
EP1668035A2 (de) 2003-09-11 2006-06-14 Critical Therapeutics, Inc. Monoklonale antikörper gegen hmgb1
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
KR20070090890A (ko) 2004-10-22 2007-09-06 메디뮨 인코포레이티드 Hmgb1에 대한 고 친화성 항체 및 이의 사용 방법
WO2007084253A2 (en) 2005-11-28 2007-07-26 Medimmune, Inc. High affinity antibodies against hmgb1 and methods of use thereof
ES2643646T3 (es) 2010-01-21 2017-11-23 The Board Of Trustees Of The University Of Arkansas Vectores de vacuna y métodos para potenciar las respuestas inmunitarias
EP2579901B1 (de) 2010-06-09 2019-08-07 The Board of Trustees of The University of Arkansas Impfstoff und verfahren zur linderung einer campylobacter-infektion
NZ711019A (en) 2013-02-14 2019-07-26 Univ Arkansas Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
BR112015023024B1 (pt) 2013-03-15 2022-04-19 The Board Of Trustees Of The University Of Arkansas Vetor de vacina e composições farmacêuticas compreendendo o mesmo
WO2017192671A1 (en) 2016-05-03 2017-11-09 The Board Of Trustees Of The University Of Arkansas Yeast vaccine vector including immunostimulatory and antigenic polypeptides and methods of using the same

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62166897A (ja) * 1986-01-20 1987-07-23 Toyo Soda Mfg Co Ltd 核内非ヒストン蛋白質に対するモノクロ−ナル抗体
EP0727487A1 (de) * 1995-02-17 1996-08-21 K.U. Leuven Research & Development Multi-Tumor abweichende Wachstumsgene
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
JP3018313B2 (ja) * 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤

Also Published As

Publication number Publication date
EP1079849B1 (de) 2002-01-02
DE69900756T2 (de) 2003-03-13
ATE211391T1 (de) 2002-01-15
ES2171086T3 (es) 2002-08-16
EP1079849A2 (de) 2001-03-07
ITMI981094A1 (it) 1999-11-19
DK1079849T3 (da) 2002-04-22
PT1079849E (pt) 2002-06-28
WO1999059609A3 (en) 2000-01-27
AU4363199A (en) 1999-12-06
WO1999059609A2 (en) 1999-11-25
IT1299583B1 (it) 2000-03-16
JP2002515445A (ja) 2002-05-28

Similar Documents

Publication Publication Date Title
DE69900756D1 (de) Verwendung von hmg proteinen zur herstellung von arzneimitteln mit zytotoxischer wirkung
DE69713112T2 (de) Zusammensetzungen und methoden zur behandlung von infektionen unter verwendung von indolicidin-analogen
MX336118B (es) Expresion hibrida y en tandem de proteinas de neisseria.
ATE254630T1 (de) Cyclosporine
FI953658A (fi) Stabiileja bakterisidisia/läpäisevyyttä parantavia proteiinituotteita ja näitä sisältäviä farmaseuttisia koostumuksia
DK1109831T3 (da) Cytotoksiske peptider modificeret ved store eller lipofile dele
DE69906128D1 (de) Reaktionsprodukte von hyaluronsäure und natürlichen aminosäuren sowie deren verwendung in kosmetischen und pharmazeutischen zusammensetzungen
ATE155486T1 (de) Zyklische peptide und ihre verwendung
PT848720E (pt) Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancros
AU6020099A (en) Methods for treatment of multiple sclerosis using peptide analogs of human myelin basic protein
DE602004001727D1 (de) Verfahren zur herstellung cyclischer peptide
DE59912185D1 (de) Verwendung von hsp70 protein
ATE364079T1 (de) Peptide mit gdp-austauschfaktorartiger wirkung, dafür kodierende nukleinsäuresequenzen, ihre herstellung und verwendung
HUT58765A (en) Process for producing peptide compounds and pharmaceutical compositions containing them as active components
ATE408685T1 (de) Antimikrobielle peptide, abstammend von ubiquicidin
BG103197A (en) Antithrombotic azacycloalkylalkanoyl peptides and pseudopeptiees
ATE86260T1 (de) Peptid-molekuele, wirksam gegen gram-positive keime.
FI961505A0 (fi) Uudet veren koaguloitumisjärjestelmässä terapeuttisesti aktiiviset peptidiyhdisteet, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
ATE235509T1 (de) Peptide zur inhibition von hpv e7 proteinen
SE9402332D0 (sv) Igf-1
WO2004013167A3 (en) Purified polypeptides from enterococcus faecalis
WO2004058811A3 (en) Crystal structures of yhhf polypeptides
WO1998051295A1 (fr) Inhibiteur de la protease du vih-1, leur procede de production, et compositions medicinales
RU94046405A (ru) Птг-соединения и содержащий их фармацевтический состав, способ получения желаемых полипептидов, нуклеотидная последовательность, бактериальный вектор экспрессии, бактериальные хозяйские клетки и составной белок

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: SICOR SOCIETA ITALIANA CORTICOSTEROIDI S.P.A., MAI

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee